MALVERN, Pa. — November 4, 2025 — Leads & Copy — Neuronetics, Inc. (NASDAQ: STIM) reported Q3 2025 revenue of $37.3 million, an 11% increase on an adjusted pro forma basis. Greenbrook clinic revenue hit $21.8 million, up 25% on an adjusted pro forma basis. The company improved cash management, with cash used in operations at $0.8 million. Neuronetics ended the quarter with $34.5 million in total cash. CEO Keith J. Sullivan will retire June 30, 2026; a search for his successor has begun.
U.S. Greenbrook clinic revenue for Q3 reached $21.8 million, showing 25% growth compared to Q3 2024 on an adjusted pro forma basis. U.S. NeuroStar Advanced Therapy System revenue was $3.5 million with 40 systems shipped.
The company reached over 229,429 global patients treated with 8.2 million treatment sessions. New York State Medicaid expanded coverage for TMS therapy, including NeuroStar Advanced Therapy, for major depressive disorder. Neuronetics received an additional $10 million in funding under the Perceptive debt agreement and extended the $2 million minimum liquidity requirement to September 2026. They also raised $7.8 million through the sale of common stock under its ATM facility.
For Q4 2025, Neuronetics expects total worldwide revenue between $40 million and $43 million. Full-year 2025 revenue is projected between $147 million and $150 million.
Investor Contact: Mike Vallie or Mark Klausner, ICR Healthcare, 443-213-0499, ir@neuronetics.com
Media Contact: EvolveMKD, 646-517-4220, NeuroStar@evolvemkd.com
Source: Neuronetics, Inc.
